CRDF

Cardiff Oncology Stock Analysis

AI Rating

Low
  • Quality1/10
  • Growth↓ 4/10
  • Value↓ 0/10
Cardiff Oncology sales and earnings growth
CRDF Growth
Neutral
  • Revenue Y/Y↓ -13.18%
  • EPS Y/Y↑ 27.37%
  • FCF Y/Y↓ -0.51%
Cardiff Oncology gross and profit margin trends
CRDF Profitability
Low
  • Gross margin ↑ 100.00%
  • EPS margin↓ -7736.30%
  • ROIC 5Y↓ -87.60%
Cardiff Oncology net debt vs free cash flow
CRDF Risk
Great
  • Debt / Equity↓ 0.0
  • Debt / FCF↓ 0.0
  • Interest coverage↓ NA

Cardiff Oncology stock volatility is in-line with the overall market. We give it a Great risk rating.

↗ More Biotechnology stocks